Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

5.38
-0.5350-9.05%
Volume:468.77K
Turnover:2.57M
Market Cap:369.86M
PE:-2.22
High:5.94
Open:5.91
Low:5.30
Close:5.91
Loading ...

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

GlobeNewswire
·
13 Jan

Optimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular Edema

TIPRANKS
·
09 Jan

EyePoint Pharmaceuticals Strengthens Board with New Appointment

TIPRANKS
·
08 Jan

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.d., Fasrs to Board of Directors

THOMSON REUTERS
·
08 Jan

Press Release: EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

Dow Jones
·
08 Jan

Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target

MT Newswires Live
·
07 Jan

Positive Outlook for EyePoint Pharmaceuticals Driven by Promising Prospects in the DME Market

TIPRANKS
·
03 Jan

EyePoint reports inducement grants under NASDAQ listing rule

TipRanks
·
17 Dec 2024

BRIEF-Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
16 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
16 Dec 2024

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Dec 2024

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

TIPRANKS
·
04 Dec 2024

EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
04 Dec 2024

EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026

THOMSON REUTERS
·
04 Dec 2024

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire
·
04 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
18 Nov 2024

Press Release: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
18 Nov 2024